Recently, the Anhui Provincial Medical Insurance Bureau and other departments jointly issued a document, which clearly included 343 traditional Chinese medicine formula granules such as Poria (196 Chinese standard and 147 provincial standard) into the scope of medical insurance payment in Anhui Province
.
And the varieties included in the medical insurance must have and meet the national standards or the provincial standards
.
At present, the formulation and release of provincial standards for traditional Chinese medicine formula granules in various provinces are actively and orderly advancing
.
At the same time, in June 2022, the State Pharmacopoeia Commission released the third batch of 4 national standards for traditional Chinese medicine formula granules.
Up to now, the total number of national standards for traditional Chinese medicine formula granules has reached 200
.
Affected by the switching of national standards and the promotion of provincial standards, many Chinese medicine formula granule enterprises were also affected in the first half of this year, such as China Resources Sanjiu and China Traditional Chinese Medicine
.
Among them, the semi-annual report of China Traditional Chinese Medicine mentioned that the turnover of the high-margin Chinese medicine formula granules business in the first half of the year was affected by the decline in sales, and the turnover accounted for a decrease of 19.
9 percentage points compared with the same period last year; Reduced the Group's consolidated gross profit margin
.
However, from the perspective of the long-term development of the industry, with the implementation of national standards and provincial standards, as well as the release of a series of favorable policies for traditional Chinese medicine granules, such as exemption from "zero markup" and full liberalization, the market for traditional Chinese medicine granules will continue to expand.
The industry predicts that by 2030, the market size of traditional Chinese medicine formula granules will reach 100 billion yuan
.
The industry believes that the current competitive landscape of the traditional Chinese medicine formula granules industry is good, with strong technical strength, and leading enterprises with obvious first-mover advantages in the traceability of the traditional Chinese medicine industry chain, the control of the quality of traditional Chinese medicine materials, production capacity and sales channels, etc.
It will become a beneficiary of industry expansion
.
Judging from the public information, many companies including Yiling Pharmaceutical, Peili Nongbenfang, and Yibai Pharmaceutical are accelerating their deployment in order to seize the market
.
For example, Yiling Pharmaceutical recently stated in an institutional survey that the company applied the quality control system of the whole industry chain to the R&D and production process of traditional Chinese medicine formula granules, and promoted the standardization of traditional Chinese medicine formula granules
.
According to reports, in accordance with the requirements of the State Food and Drug Administration and other relevant departments, Yiling Pharmaceutical has on the one hand increased investment to speed up the R&D and filing of new standard formula granules (national standard/provincial standard).
Listing filing work
.
On the other hand, through measures such as increasing the number of bases for TCM formula granules, expanding the production capacity of TCM formula granules, and increasing the sales team, while basing itself on the advantageous market in Hebei, we will seize the opportunity to fully open up the formula granule market nationwide, and deploy TCM formula granules domestically.
market
.
In the interim performance report, Peli Nong mentioned that looking forward to the future, in the traditional Chinese medicine formula granules segment, the Group will continue to maintain high-quality concentrated traditional Chinese medicine formula granules products, actively develop innovative health products to enrich the product portfolio, and focus on Online marketing of the Group's competitive products to reach a wider customer base, thereby preparing for a recovery in the retail market
.
For another example, Yibai Pharmaceutical disclosed on August 27 the company's progress announcement on the capital increase and share expansion of its subsidiary, Guizhou Yibai Traditional Chinese Medicine Formula Granules Pharmaceutical Co.
,
Ltd.
According to the Agreement on Capital Increase and Share Expansion, on June 30, 2022, Yibai Formula Granules received a capital increase of RMB 80 million from the Guizhou Agricultural Development Fund
.
On August 26, 2022, Yibai Formula Granules obtained the "Business License" issued by the Municipal Supervision Bureau of Guanshanhu District, Guiyang City
.
As of the disclosure date of this announcement, all funds for the capital increase and share expansion have been received, and the industrial and commercial registration procedures for the equity change of Yibai Formula Granules have been completed.
The company will enjoy the shareholders' rights and obligations of Yibai Formula Granules in accordance with the shareholding ratio
.
The company stated that this capital increase and share expansion will help enhance the company's core competitiveness and achieve sustainable development of the company
.
